Rahul D. Ballal is Director at Enliven Therapeutics, Inc. (ELVN). They have made 3 open-market trades across 1 company since 2020, most recently 2026-06-18.
CIK 0001805097
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AGIO | SELL · 10b5-1 | 2024-11-07 | 2024-11-12 | $55.73 | $2.1M | -5.7% | -35.3% | -42.5% |
| ELVN | SELL · 10b5-1 | 2024-10-08 | 2024-10-10 | $28.17 | $587K | +8.3% | +3.3% | -9.8% |
| ELVN | SELL · 10b5-1 | 2024-04-10 | 2024-04-12 | $23.44 | $1.6M | -15.8% | +18.0% | +15.9% |
| ELVN | SELL · 10b5-1 | 2024-04-04 | 2024-04-08 | $19.15 | $133K | -6.8% | +29.2% | +18.4% |
| ELVN | SELL · 10b5-1 | 2024-04-01 | 2024-04-03 | $19.08 | $124K | +5.1% | +19.4% | +14.4% |
| ELVN | SELL · 10b5-1 | 2024-03-20 | 2024-03-22 | $19.16 | $509K | +0.8% | -4.6% | +14.0% |
| IMRA | SELL | 2023-02-22 | 2023-02-22 | $4.66 | $306K | +140.0% | +116.9% | +116.9% |
| IMRA | SELL | 2023-01-30 | 2023-02-01 | $3.91 | $44K | +15.1% | +147.8% | +147.8% |
| IMRA | SELL | 2020-12-17 | 2020-12-21 | $25.00 | $125K | +5.0% | -37.6% | -55.9% |
| IMRA | SELL · 10b5-1 | 2020-12-14 | 2020-12-16 | $25.00 | $25 | -13.1% | -43.5% | -57.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.